Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$1.16 - $1,030.00
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$25.10M
Enterprise Value$60.63M
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding18,589,832
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap2.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-3.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageElimination of recorded debt meaningfully reduces financial risk and interest obligations, improving capital structure flexibility. Over a multi-month horizon this lowers default and covenant risk, giving management more optionality to prioritize R&D, licensing, or strategic partnerships without debt constraints.
Positive Equity CushionA positive and rising equity base provides a durable capital buffer to absorb ongoing operating losses and support regulatory and clinical activities. This sustained equity position helps preserve creditor confidence and supports negotiations for non-dilutive partnerships or milestone financing.
Focused Clinical-Stage PipelineA narrow, modality-focused pipeline (antibody-based therapies for autoimmune/inflammatory diseases) concentrates scientific expertise and resource allocation, improving development efficiency and partner appeal. This focused strategy supports clearer milestone-driven value creation over several months.
Bears Say
Zero Revenue BaseAbsence of product or service revenue leaves the company fully dependent on external financing and milestone events to fund operations. This structural lack of cash inflows increases dilution risk and means long-term viability hinges on clinical success or sustained financing access rather than operating performance.
Persistent, Accelerating Cash BurnConsistent negative operating and free cash flow, with a notable TTM deterioration, creates an ongoing funding requirement. Over a 2-6 month horizon this raises the probability of additional equity or strategic financings, constraining autonomy, diluting shareholders, and limiting the ability to sustain or expand clinical programs.
Smaller Balance Sheet / Reduced AssetsA materially reduced asset base limits operational flexibility to absorb setbacks or scale trials. With lower tangible resources and a smaller operating footprint, the company may face harder trade-offs on program prioritization, weaker bargaining power with partners, and reduced resilience during lengthy clinical timelines.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $1.16 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $25.10M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -$0.136 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.136.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 18,589,832 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.642%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Ownership Overview
3.61% Insiders
0.36% Mutual Funds
― Other Institutional Investors
96.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---